DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.1% – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price shot up 8.1% on Tuesday . The company traded as high as $16.70 and last traded at $16.8730. 163,793 shares were traded during trading, a decline of 45% from the average daily volume of 296,862 shares. The stock had previously closed at $15.61.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, June 29th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Guggenheim restated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Citizens Jmp boosted their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Price Performance

The firm has a market cap of $999.05 million, a PE ratio of -3.76 and a beta of -0.95. The company has a 50-day simple moving average of $17.89 and a 200-day simple moving average of $19.75.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, equities research analysts predict that DBV Technologies S.A. will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in DBV Technologies during the 1st quarter valued at about $20,146,000. Vivo Capital LLC increased its position in DBV Technologies by 8.4% during the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of DBV Technologies during the first quarter valued at about $21,159,000. Royal Bank of Canada raised its holdings in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after buying an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP purchased a new position in DBV Technologies in the 1st quarter worth $5,536,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.